Michael Macaluso, CEO and Chairman of Ampio, noted "Ampio already possesses a comprehensive portfolio of issued patents and pending patent applications on Ampion[TM], including composition of matter, methods of use and synthesis patents of the naturally occurring innate, human, anti-inflammatory small molecule diketopiperazine
Received notification of the granting of a Canadian patent with broad claims directed to compositions containing either DA-DKP, a cyclic dipeptide diketopiperazine
, which is the active ingredient of Ampion[TM], but also extends to many other diketopiperazines
fragment of human serum albumin modulates T-lymphocyte cytokine production through rap1.
The protected compositions contain either DA-DKP, a cyclic dipeptide diketopiperazine
, which is the active ingredient of Ampion[logical not][sup.